Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The filing metadata references "REVVITY, INC.", but the document text identifies the registrant as PerkinElmer, Inc.)
Reporting Date: September 7, 2011
Event: Entry into a Material Definitive Agreement to acquire Caliper Life Sciences, Inc. ("Caliper") and securing financing for the transaction.
Key Financial Metrics and Transaction Terms
- Merger Consideration: $10.50 in cash per share of Caliper common stock.
- Financing Facility: Up to $400 million in senior unsecured bridge loans (364-day term).
- Interest Rates: LIBOR + 300 basis points or Base Rate + 200 basis points (subject to increase).
- Termination Fee: $12.8 million payable by Caliper to PerkinElmer under specified termination circumstances.
- Existing Debt: Includes 6.0% Notes due 2015 and a $650 million revolving credit facility.
- Financial Covenants (Bridge Facility):
- Maximum Total Debt to Total Capitalization Ratio: 40% (or Total Debt to EBITDA of 3.5 to 1 if not Investment Grade).
- Minimum Consolidated EBITDA to Total Interest Expense: 3 to 1.
Material Changes and Strategic Actions
The filing reports the execution of a Merger Agreement to acquire Caliper Life Sciences, Inc., a move intended to expand PerkinElmer's portfolio. Concurrently, the company secured a commitment letter for a $400 million bridge facility to fund the acquisition, refinance existing debt, and cover transaction fees. The transaction is subject to Caliper stockholder approval and regulatory clearance (Hart-Scott-Rodino).
Guidance, Outlook, and Risks
Outlook and Financing Strategy: PerkinElmer intends to issue up to $400 million in permanent securities ("Take-Out Financing") to replace the bridge loans. If the company's credit rating falls below BBB- (S&P) or Ba1 (Moody's), lenders may demand immediate issuance of permanent financing.
Risks and Contingencies:
- Regulatory Approval: The merger is contingent on the expiration of waiting periods under antitrust laws.
- Stockholder Approval: Requires adoption of the Merger Agreement by Caliper's stockholders.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as market decline, integration challenges, regulatory changes, and supply chain disruptions.
- Covenant Compliance: The bridge facility includes strict negative covenants regarding liens, investments, indebtedness, and restricted payments, with baskets varying based on credit rating status.
Investor Verification Checklist
- Verify the final approval status of the Merger Agreement by Caliper Life Sciences stockholders.
- Confirm the successful issuance of permanent "Take-Out Financing" to replace the $400 million bridge loan before maturity.
- Monitor the company's credit rating to ensure it remains above the thresholds (BBB-/Ba1) that trigger mandatory refinancing demands.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific representations and warranties not detailed in this summary.
- Assess the impact of the $12.8 million termination fee provision on potential deal break scenarios.